HPV  ||| S:0 E:4 ||| NNP
testing  ||| S:4 E:12 ||| NN
in  ||| S:12 E:15 ||| IN
prevention  ||| S:15 E:26 ||| NN
of  ||| S:26 E:29 ||| IN
cervical  ||| S:29 E:38 ||| JJ
cancer ||| S:38 E:44 ||| NN
:  ||| S:44 E:46 ||| :
practices  ||| S:46 E:56 ||| NNS
and  ||| S:56 E:60 ||| CC
current  ||| S:60 E:68 ||| JJ
trends  ||| S:68 E:75 ||| NNS
Robust  ||| S:75 E:82 ||| JJ
evidence  ||| S:82 E:91 ||| NN
supports  ||| S:91 E:100 ||| VBZ
new  ||| S:100 E:104 ||| JJ
strategies  ||| S:104 E:115 ||| NNS
for  ||| S:115 E:119 ||| IN
prevention  ||| S:119 E:130 ||| NN
of  ||| S:130 E:133 ||| IN
cervical  ||| S:133 E:142 ||| JJ
cancer  ||| S:142 E:149 ||| NN
based  ||| S:149 E:155 ||| VBN
on  ||| S:155 E:158 ||| IN
the  ||| S:158 E:162 ||| DT
detection  ||| S:162 E:172 ||| NN
of  ||| S:172 E:175 ||| IN
persistent  ||| S:175 E:186 ||| JJ
Human  ||| S:186 E:192 ||| JJ
papillomavirus  ||| S:192 E:207 ||| NNS
( ||| S:207 E:208 ||| -LRB-
HPV ||| S:208 E:211 ||| NNP
)  ||| S:211 E:213 ||| -RRB-
infection ||| S:213 E:222 ||| NN
,  ||| S:222 E:224 ||| ,
the  ||| S:224 E:228 ||| DT
causative  ||| S:228 E:238 ||| JJ
agent  ||| S:238 E:244 ||| NN
of  ||| S:244 E:247 ||| IN
the  ||| S:247 E:251 ||| DT
disease ||| S:251 E:258 ||| NN
.  ||| S:258 E:260 ||| .
New  ||| S:260 E:264 ||| NNP
HPV  ||| S:264 E:268 ||| NNP
infection  ||| S:268 E:278 ||| NN
is  ||| S:278 E:281 ||| VBZ
usually  ||| S:281 E:289 ||| RB
benign  ||| S:289 E:296 ||| JJ
and  ||| S:296 E:300 ||| CC
transient ||| S:300 E:309 ||| NN
,  ||| S:309 E:311 ||| ,
while  ||| S:311 E:317 ||| IN
persistent  ||| S:317 E:328 ||| JJ
infection  ||| S:328 E:338 ||| NN
with  ||| S:338 E:343 ||| IN
one  ||| S:343 E:347 ||| CD
of  ||| S:347 E:350 ||| IN
-high  ||| S:350 E:356 ||| JJ
risk  ||| S:356 E:361 ||| NN
HPV  ||| S:361 E:365 ||| NNP
explains  ||| S:365 E:374 ||| VBZ
almost  ||| S:374 E:381 ||| RB
all  ||| S:381 E:385 ||| RB
of  ||| S:385 E:388 ||| IN
these  ||| S:388 E:394 ||| DT
cancers ||| S:394 E:401 ||| NNS
.  ||| S:401 E:403 ||| .
In  ||| S:403 E:406 ||| IN
fact ||| S:406 E:410 ||| NN
,  ||| S:410 E:412 ||| ,
the  ||| S:412 E:416 ||| DT
detection  ||| S:416 E:426 ||| NN
of  ||| S:426 E:429 ||| IN
one  ||| S:429 E:433 ||| CD
of  ||| S:433 E:436 ||| IN
the  ||| S:436 E:440 ||| DT
12  ||| S:440 E:443 ||| CD
oncogenic  ||| S:443 E:453 ||| CD
HPV  ||| S:453 E:457 ||| NNS
increase  ||| S:457 E:466 ||| VB
the  ||| S:466 E:470 ||| DT
sensitivity  ||| S:470 E:482 ||| NN
of  ||| S:482 E:485 ||| IN
the  ||| S:485 E:489 ||| DT
screening  ||| S:489 E:499 ||| NN
and  ||| S:499 E:503 ||| CC
predicts ||| S:503 E:511 ||| VBZ
,  ||| S:511 E:513 ||| ,
sooner  ||| S:513 E:520 ||| RBR
than  ||| S:520 E:525 ||| IN
cytology ||| S:525 E:533 ||| NN
,  ||| S:533 E:535 ||| ,
the  ||| S:535 E:539 ||| DT
risk  ||| S:539 E:544 ||| NN
of  ||| S:544 E:547 ||| IN
precancerous  ||| S:547 E:560 ||| JJ
lesions ||| S:560 E:567 ||| NNS
,  ||| S:567 E:569 ||| ,
the  ||| S:569 E:573 ||| DT
high  ||| S:573 E:578 ||| JJ
grade  ||| S:578 E:584 ||| NN
of  ||| S:584 E:587 ||| IN
cervical  ||| S:587 E:596 ||| FW
intraepithelial  ||| S:596 E:612 ||| FW
neoplasia  ||| S:612 E:622 ||| FW
( ||| S:622 E:623 ||| -LRB-
HG  ||| S:623 E:626 ||| NNP
CIN ||| S:626 E:629 ||| NNP
) ||| S:629 E:630 ||| -RRB-
.  ||| S:630 E:632 ||| .
Negative  ||| S:632 E:641 ||| JJ
HPV  ||| S:641 E:645 ||| NNP
detection  ||| S:645 E:655 ||| NN
gives  ||| S:655 E:661 ||| VBZ
instantaneously  ||| S:661 E:677 ||| VBG
a  ||| S:677 E:679 ||| DT
reassurance  ||| S:679 E:691 ||| JJ
close  ||| S:691 E:697 ||| NN
to  ||| S:697 E:700 ||| TO
100 ||| S:700 E:703 ||| CD
%  ||| S:703 E:705 ||| NN
of  ||| S:705 E:708 ||| IN
absence  ||| S:708 E:716 ||| NN
of  ||| S:716 E:719 ||| IN
disease  ||| S:719 E:727 ||| NN
at  ||| S:727 E:730 ||| IN
risk  ||| S:730 E:735 ||| NN
( ||| S:735 E:736 ||| -LRB-
while  ||| S:736 E:742 ||| IN
cytology  ||| S:742 E:751 ||| JJ
detection  ||| S:751 E:761 ||| NN
is  ||| S:761 E:764 ||| VBZ
less  ||| S:764 E:769 ||| JJR
than  ||| S:769 E:774 ||| IN
60 ||| S:774 E:776 ||| CD
% ||| S:776 E:777 ||| NN
)  ||| S:777 E:779 ||| -RRB-
and  ||| S:779 E:783 ||| CC
almost  ||| S:783 E:790 ||| RB
guarantees  ||| S:790 E:801 ||| VBZ
protection  ||| S:801 E:812 ||| NN
of  ||| S:812 E:815 ||| IN
the  ||| S:815 E:819 ||| DT
absence  ||| S:819 E:827 ||| NN
of  ||| S:827 E:830 ||| IN
HG  ||| S:830 E:833 ||| NNP
CIN  ||| S:833 E:837 ||| NNP
over  ||| S:837 E:842 ||| IN
a  ||| S:842 E:844 ||| DT
prolonged  ||| S:844 E:854 ||| JJ
period ||| S:854 E:860 ||| NN
,  ||| S:860 E:862 ||| ,
allowing  ||| S:862 E:871 ||| VBG
lengthening  ||| S:871 E:883 ||| NNS
safely  ||| S:883 E:890 ||| RB
the  ||| S:890 E:894 ||| DT
screening  ||| S:894 E:904 ||| NN
interval  ||| S:904 E:913 ||| NN
to  ||| S:913 E:916 ||| TO
5  ||| S:916 E:918 ||| CD
years ||| S:918 E:923 ||| NNS
.  ||| S:923 E:925 ||| .
Pooled  ||| S:925 E:932 ||| JJ
HPV-based  ||| S:932 E:942 ||| JJ
screening  ||| S:942 E:952 ||| NN
tests  ||| S:952 E:958 ||| NNS
decrease  ||| S:958 E:967 ||| VB
the  ||| S:967 E:971 ||| DT
specificity  ||| S:971 E:983 ||| NN
of  ||| S:983 E:986 ||| IN
the  ||| S:986 E:990 ||| DT
screening  ||| S:990 E:1000 ||| NN
and  ||| S:1000 E:1004 ||| CC
increases  ||| S:1004 E:1014 ||| VBZ
the  ||| S:1014 E:1018 ||| DT
number  ||| S:1018 E:1025 ||| NN
of  ||| S:1025 E:1028 ||| IN
colposcopy ||| S:1028 E:1038 ||| NN
.  ||| S:1038 E:1040 ||| .
New  ||| S:1040 E:1044 ||| JJ
strategies  ||| S:1044 E:1055 ||| NNS
can  ||| S:1055 E:1059 ||| MD
significantly  ||| S:1059 E:1073 ||| RB
improve  ||| S:1073 E:1081 ||| VB
the  ||| S:1081 E:1085 ||| DT
specificity  ||| S:1085 E:1097 ||| NN
of  ||| S:1097 E:1100 ||| IN
HPV  ||| S:1100 E:1104 ||| NNP
screening  ||| S:1104 E:1114 ||| NN
without  ||| S:1114 E:1122 ||| IN
a  ||| S:1122 E:1124 ||| DT
significant  ||| S:1124 E:1136 ||| JJ
impact  ||| S:1136 E:1143 ||| NN
on  ||| S:1143 E:1146 ||| IN
the  ||| S:1146 E:1150 ||| DT
sensitivity ||| S:1150 E:1161 ||| NN
,  ||| S:1161 E:1163 ||| ,
including  ||| S:1163 E:1173 ||| VBG
exclusion  ||| S:1173 E:1183 ||| NN
of  ||| S:1183 E:1186 ||| IN
women  ||| S:1186 E:1192 ||| NNS
less  ||| S:1192 E:1197 ||| RBR
than  ||| S:1197 E:1202 ||| IN
30  ||| S:1202 E:1205 ||| CD
years ||| S:1205 E:1210 ||| NNS
,  ||| S:1210 E:1212 ||| ,
the  ||| S:1212 E:1216 ||| DT
use  ||| S:1216 E:1220 ||| NN
of  ||| S:1220 E:1223 ||| IN
HPV  ||| S:1223 E:1227 ||| NNP
DNA  ||| S:1227 E:1231 ||| NNP
genotyping  ||| S:1231 E:1242 ||| NN
tests  ||| S:1242 E:1248 ||| NNS
with  ||| S:1248 E:1253 ||| IN
recognition  ||| S:1253 E:1265 ||| NN
of  ||| S:1265 E:1268 ||| IN
the  ||| S:1268 E:1272 ||| DT
most  ||| S:1272 E:1277 ||| JJS
HPV  ||| S:1277 E:1281 ||| NN
at  ||| S:1281 E:1284 ||| IN
risk ||| S:1284 E:1288 ||| NN
,  ||| S:1288 E:1290 ||| ,
the  ||| S:1290 E:1294 ||| DT
16  ||| S:1294 E:1297 ||| CD
and  ||| S:1297 E:1301 ||| CC
18  ||| S:1301 E:1304 ||| CD
types ||| S:1304 E:1309 ||| NNS
.  ||| S:1309 E:1311 ||| .
HPV  ||| S:1311 E:1315 ||| NNP
alone  ||| S:1315 E:1321 ||| RB
can  ||| S:1321 E:1325 ||| MD
be  ||| S:1325 E:1328 ||| VB
used  ||| S:1328 E:1333 ||| VBN
as  ||| S:1333 E:1336 ||| IN
a  ||| S:1336 E:1338 ||| DT
screening  ||| S:1338 E:1348 ||| NN
tool  ||| S:1348 E:1353 ||| NN
in  ||| S:1353 E:1356 ||| IN
women  ||| S:1356 E:1362 ||| NNS
of  ||| S:1362 E:1365 ||| IN
30  ||| S:1365 E:1368 ||| CD
years  ||| S:1368 E:1374 ||| NNS
+  ||| S:1374 E:1376 ||| VBP
with  ||| S:1376 E:1381 ||| IN
a  ||| S:1381 E:1383 ||| DT
cytology  ||| S:1383 E:1392 ||| JJ
triage  ||| S:1392 E:1399 ||| NN
or  ||| S:1399 E:1402 ||| CC
immunocytochemical  ||| S:1402 E:1421 ||| JJ
staining  ||| S:1421 E:1430 ||| NN
of  ||| S:1430 E:1433 ||| IN
cyto  ||| S:1433 E:1438 ||| JJ
slides  ||| S:1438 E:1445 ||| NNS
for  ||| S:1445 E:1449 ||| IN
p16  ||| S:1449 E:1453 ||| CD
of  ||| S:1453 E:1456 ||| IN
HPV  ||| S:1456 E:1460 ||| NNP
positive ||| S:1460 E:1468 ||| JJ
.  ||| S:1468 E:1470 ||| .
Co-testing  ||| S:1470 E:1481 ||| NNP
( ||| S:1481 E:1482 ||| -LRB-
cytology+  ||| S:1482 E:1492 ||| NNP
HPV  ||| S:1492 E:1496 ||| NNP
test ||| S:1496 E:1500 ||| NN
)  ||| S:1500 E:1502 ||| -RRB-
was  ||| S:1502 E:1506 ||| VBD
adopted  ||| S:1506 E:1514 ||| VBN
in  ||| S:1514 E:1517 ||| IN
the  ||| S:1517 E:1521 ||| DT
USA  ||| S:1521 E:1525 ||| NNP
as  ||| S:1525 E:1528 ||| IN
a  ||| S:1528 E:1530 ||| DT
standard  ||| S:1530 E:1539 ||| JJ
screening  ||| S:1539 E:1549 ||| NN
option ||| S:1549 E:1555 ||| NN
.  ||| S:1555 E:1557 ||| .
